Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
Open Access
- 24 September 2021
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open QuestionKeywords
This publication has 16 references indexed in Scilit:
- Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathwaysOncotarget, 2015
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015
- Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trialOncotarget, 2015
- Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasisInternational Journal of Cancer, 2011
- Liver Metastases From Colorectal Cancer Treated With Conventional and Antiangiogenetic ChemotherapyJournal of Computer Assisted Tomography, 2011
- Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from ImagingClinical Cancer Research, 2009
- Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered ChemotherapyClinical Cancer Research, 2007
- Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal CancerSeminars in Oncology, 2006
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995